Core Insights - Labcorp Holdings Inc. is valued at a market cap of $23 billion and is a leading global provider of comprehensive laboratory services [1] - The company operates through its Diagnostics Laboratories and Biopharma Laboratory Services segments, offering a wide range of testing, specialty diagnostics, and drug development solutions [1][2] Financial Performance - Labcorp's shares have fallen 2.7% from its 52-week high of $283.47 but have risen 5.4% over the past three months, outperforming The Health Care Select Sector SPDR Fund's (XLV) 2.6% gain [3] - Year-to-date, Labcorp's stock is up 20.3%, significantly exceeding XLV's 1.1% decline, and has soared 24.2% over the past 52 weeks compared to XLV's 12.4% decrease [4] - The company reported strong Q2 2025 results with adjusted EPS of $4.35 and revenues of $3.53 billion, surpassing estimates [5] - Growth in Q2 was driven by Diagnostics Laboratories, which grew 8.9% to $2.75 billion, and Biopharma Laboratory Services, which rose 11% to $784.8 million [5] - Full-year 2025 guidance has been raised, with revenue growth now expected at 7.5% - 8.6% and adjusted EPS at $16.05 - $16.50 [5] Market Position and Analyst Sentiment - Despite rival Quest Diagnostics Incorporated (DGX) outperforming Labcorp on a year-to-date basis with a 22.4% increase, Labcorp has outperformed DGX over the past 52 weeks [6] - Analysts maintain a bullish outlook on Labcorp, with a consensus rating of "Strong Buy" from 18 analysts and a mean price target of $295.53, representing a 5.9% premium to current levels [6]